Form 4: Cytek Biosciences Director Reports Stock Transaction
Insider Transaction (Form 4)
Richard Chin, a Director of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 6,107 Common Stock on August 18, 2026; holds 28,499 after (Direct).
- Option exercise/conversion: disposed of 6,107 Restricted Stock Units on August 18, 2026; holds 44,790 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Richard Chin — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock | 6,107 | — | — | 28,499 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 6,107 | — | — | 44,790 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (6,107 shares) |
| 2026-08-18 | Option exercise/conversion (6,107 shares) |
Keywords
insider transaction, Form 4, CTKB, Cytek Biosciences, Inc., neutral, Richard Chin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.